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Myxoid-round cell liposarcoma. 
Note 
Sarcomas are relatively rare malignant tumours and 
comprise less than 10% of all cancers. Classical 
classifications of sarcomas are based on the site of 
tumour (bone or soft tissue). Soft tissue sarcoma (STS) 
is the collective term used for malignancies arising i  
muscles, fat, vessels, the peripheral nervous system and 
fibrous tissue.  
Histopathologic examination of such tumours has 
revealed a large number of distinct entities, each 
displaying its own morphologic and clinical 
characteristics.  
Cytogenetic and molecular genetic analyses have 
shown that some of these STS are characterized by 
specific chromosomal translocations, whereas other 
STS show complex genetic aberrations.  
Liposarcoma is the most common soft tissue 
malignancy in adults accounting for at least 20% of all 
sarcomas in this age group. Myxoid-round cell 
liposarcoma is a subtype of liposarcoma characterized 
by the presence of the reciprocal chromosomal 
translocation t(12;16)(q13;p11).  
This translocation creates the FUS-DDIT3 chimeric 
gene. 
Clinics and pathology 
 










Liposarcoma is a lipogenic tumour subclassified into 
four main histologic groups, including well-
differentiated liposarcoma (lipoma-like and sclerosing 
types), myxoid-round cell liposarcoma, pleomorphic 
liposarcoma, and dedifferentiated liposarcoma. The 
histologic group is predictive of both the clinical course 
of the disease and the ultimate prognosis. 
Cytogenetics 
Cytogenetics Morphological 
Cytogenetics analyses have shown that several 
lipogenic tumours are characterized by specific 
chromosomal abnormalities, the best known was the 
reciprocal translocation t(12;16)(q13;p11) of myxoid-
round cell liposarcoma, described about twenty years 
ago.This translocation results in a fusion gene 
consisting of the 5' part of the FUS (TLS) gene andthe 
complete coding region of the CHOP gene (see fig.1). 




DNA / RNA 
The FUS gene consists of 15 exons located within 11 
kb of genomic DNA, and the exon 1 contains a 72-bp 
untranslated region and the translation initiation c don.  
The location of the FUS gene was identified as 16p1 
by the site of the breakpoint in the translocation. The 
assignment was further narrowed to 16p11.2 by 
cytogenetic studies. FUS is rearranged in myxoid 
liposarcomas in the characteristic chromosomal 
translocation t(12;16)(q13;p11). 
Protein 
The FUS protein, provisionally designated TLS 
(translocated in liposarcoma), and then called FUS, 
contains an RNA-recognition motif and is a component 
of nuclear riboprotein complexes.  
Lack of FUS in mice causes lethallity into neonatal 
period, it influences lymphocyte development in a non-
cell-intrinsic manner, it has an intrinsic role in the 
proliferative responses of B cells to specific mitogenic  
stimuli, and it is required for the maintenance of 
genomic stability. The involvement of a nuclear 
riboprotein in these processes in vivo indicates that 
FUS is important in genome maintenance. 
Somatic mutations 
Variants: FUS has been also shown a partner of gene 
fusions linked in other malignances: fused to ERG in 
acute myeloid leukaemia with t(16:21)(p11;q22), fused 
to CREB3L2 in low-grade fibromyxoid .sarcoma 
(LGFMS) by a translocation between chromosome 
bands 7q33-q34 (CREB3L2) and 16p11 (FUS) or fused 




DNA / RNA 
The DDIT3 gene was isolated from human cells and 
has a high level of conservation with previously 
described hamster gene. Each is composed of 4 exons 
with intron/exon junctions maintained at identical 
positions. They showed 91% identity in amino acid 
sequence and 78% identity in nucleotide sequence. Th  
gene is located on chromosome 12 (12q13.1-q13.2). 
Protein 
CHOP (C/EBP-homologous protein) is a nuclear 
protein which was identified as a dominant-negative 
inhibitor of the transcription factors C/EBP and LAP.  
The protein also was called DDIT3 for DNA damage-
inducible transcript 3' and GADD153 for 'growth 
arrest- and DNA damage-inducible gene.  
DDIT3 is consistently rearranged in myxoid 
liposarcomas in the characteristic chromosomal 
translocation t(12;16)(q13;p11). Its molecular 
characterization showed that the DDIT3 gene is fused 
with a gene on chromosome 16 named FUS. 
Somatic mutations 
Variants: An analysis of peripheral blood samples 
from 19 patients with myxoid liposarcoma linked to 
t(12;16) and from 1 patient with myxoid liposarcoma 
associated to t(12;22;20) chromosomal translocation, 
resulting in the fusion of the DDIT3 and EWS genes, 
found FUS-DDIT3 hybrid fragments in 3 patients with 
t(12;16) and the EWS-DDIT3 hybrid in the patient wih 
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Result of the chromosomal anomaly 
Hybrid Gene 
 
The FUS-CHOP fusion genes consist of the 5’ promoter region and exons 1-5 or, more rarely, 1-7 or 1-8 of FUS gene fused to the 




Oncogenic properties Transcriptional control of the 
fusion gene is dominated by the FUS housekeeping 
type of regulatory region, leading to stable expression 
of the fusion protein in tumor cells. The transforming 
properties of the FUS-DDIT3 fusion protein have been 
demonstrated in NIH 3T3 cells and fibroblasts. In the
FUS-DDIT3 fusion, transcriptional activation is 
specifically conferred on the chimeric protein by the 
FUS segment after the translocation event. The portion 
of FUS that is present in the FUS-DDIT3 and FUS-
ERG fusion proteins is similar and this part has been 
shown to be an autonomous transcriptional activation 
domain. The protein most likely functions as an 
abnormal transcription factor acting on a number of 
downstream target genes. 
Mouse models In vivo, mice expressing FUS-DDIT3 
develop liposarcomas. Overexpression of FUS-DDIT3 
transgene driven by the elongation factor 1alpha 
(EF1alpha) promoter to all tissues, results in most of 
the symptoms of human liposarcomas, including the 
presence of lipoblasts with round nuclei, accumulation 
of intracellular lipid, induction of adipocyte-specifi  
genes and a concordant block in the differentiation 
program (see figure 2). No tumours of other tissues 
were found in these transgenic mice despite widespread 
activity of the EF1alpha promoter. This establishes 
FUS-DDIT3 overexpression as a key determinant of 
human liposarcomas and provided the first in vivo 
evidence for a link between a fusion gene created by a
chromosomal translocation and a solid tumour. In 
contrast, transgenic mice expressing high levels of 
DDIT3, which lacks the FUS domain, do not develop 
any tumour but consistently show the accumulation of a 
glycoprotein material within the terminally 
differentiated adipocytes, a characteristic figure of 
liposarcomas associated with FUS-DDIT3. However, 
transgenic mice expressing the altered form of DDIT3-
FUS (created by the in frame fusion of the FUS domain 
to the carboxy end of DDIT3) developed liposarcomas. 
The characteristics of the liposarcomas arising in the 
DDIT3-FUS mice were very similar to those previously 
observed in the FUS-DDIT3 transgenic mice indicating 
that the FUS domain is required not only for 
transformation but also influences the phenotype of the 
tumor cells. These results provide evidence that the 
FUS domain of FUS-DDIT3 plays a specific and 
critical role in the pathogenesis of liposarcoma. In this 
sense, when mice expressing the FUS domain are 
crossed with DDIT3-transgenic mice to generate the 
double-transgenic FUSxDDIT3, these animals develop 
liposarcoma. These results provide genetic evidence 
that FUS and DDIT3 domains function in trans for the
mutual restoration of liposarcoma, and identify a new 
mechanism of tumour-associated fusion genes which 
might have impact beyond myxoid liposarcoma. 
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